DAO and schizophrenia: In contrast to NMDAR antagonists, two recent randomized, double-blind, placebo-controlled trials demonstrated that adjunctive therapy with benzoate, a D-amino acid oxidase inhibitor, improved cognitive function and the negative symptoms of patients with schizophrenia [70,71].